Are you considering starting birth control and are not on it yet? Help us learn how birth control affects risk of blood clots! We are looking to learn more about blood clot risk when women with sickle cell disease start birth control, and we need healthy women for comparison. This will involve a survey and blood draw at the visit to start birth control and then 3 months afterward. A small compensation is provided.
We are developing a computer-based tool for people who have cancers of the blood, bone marrow, and lymph nodes. This tool will help us understand what is most important to patients when it comes to the results of their treatment. We are looking for healthy volunteers (those without cancer) to help us test the usability of this tool.
Hereditary Hemorrhagic Telangiectasia (HHT) is a condition that causes abnormal blood vessels to form. This goal of this study is to look at people who have HHT, with and without brain arteriovenous malformations (BAVMs). The purpose of this study is to learn more about brain AVMs (BAVMs) and bleeding in patients with HHT. We plan to study risk factors for rupture of BAVMs and also for other bleeding and features of HHT disease, including primarily genetics and imaging characteristics of the BAVMs. We hope that knowledge about risk factors will help improve the care and management of HHT patients.
To have a well phenotyped cohort of people with sickle cell disease in order to examine risk factors for end organ disease through the creation of a multi-site registry and to develop a repository for the long-term storage of patient samples (whole blood, peripheral blood, serum) along with corresponding demographic and clinical information to allow for clinical and laboratory correlations.
This study will evaluate the use of MMUD PBSC in adults and explore the safety and efficacy of MMUD BM in pediatric recipients with hematological malignancies who may lack other donor options.
The purpose of this research study is to improve safety measures and reduce stressors associated with lumen hub-clave seizures when caring for patients with CVCs. The primary outcome of the pilot study is to document the types and frequency of workarounds employed, current disinfection techniques, and the stressors of those caring for and accessing CVCs.
To further the scientific knowledge base for the diagnosis, understanding, and management of sickle cell disease (SCD) by assembling data collected in routine clinical care and closed clinical trials. This umbrella Data Hub Protocol will permit the creation of a patient-level data repository obtained from individuals, or the records of individuals, with SCD thereby collecting key information and identifying gaps that will help advance SCD treatment and research.
The ASH Registry d/b/a the ASH Research Collaborative (ASH RC), is a non-profit organization established by the American Society of Hematology (ASH) in 2018 that aims to improve the lives of those affected by blood diseases by fostering collaborative partnerships to accelerate progress in hematology. The foundation of the ASH RC is its Data Hub, a technology platform that facilitates the exchange of information by aggregating in one place, and making available for inquiry, research-grade data on hematologic diseases. In 2019, ASH RC launched its first research initiative, the Sickle Cell Disease (SCD) Clinical Trials Network (CTN), with the goal of optimizing SCD clinical research operations. As part of its core functions, the SCD-CTN leverages the Data Hub to collect key information and identify gaps that will help advance SCD research and treatment. The primary goal of the Data Hub is to further the scientific knowledge base for the diagnosis, understanding,
Can we lower the chances of your acute myeloid leukemia (AML) growing by adding a drug to the usual combination of drugs? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your AML. The usual approach is defined as care most people get for AML.
To determine if patients that are 75 years of age or older who were recently diagnosed with DLBCL be able to take the study drug CC-486 (oral azacitidine) plus the standard drug therapy that fights cancer cells for at least 4 cycles of therapy (a cycle = 21 days; 4 cycles is 12 weeks) without significantly more side effects than patients taking the standard drug therapy alone; have longer, shorter, or the same amount of time without the disease getting worse (progression) than patients taking the standard drug therapy alone; live longer, live the same amount of time, or live a shorter amount of time than patients taking the standard drug therapy alone. This study is being done to find out if this approach is better or worse than the usual approach for the DLBCL. The usual approach is defined as care most people get for DLBCL.